RT info:eu-repo/semantics/article
T1 Effectiveness of Comirnaty® vaccine and correlates of immunogenicity and adverse reactions: A single-center prospective case series study
A1 Fernández Lázaro, Diego
A1 Garrosa García, Manuel
A1 Sánchez Serrano, Nerea
A1 Garrosa, Evelina
A1 Jiménez Callejo, Elena
A1 Pardo Yanguas, María Dolores
A1 Mielgo Ayuso, Juan Francisco
A1 Seco Calvo, Jesús
K1 Elderly
K1 Personas de edad
K1 Healthcare workers
K1 Medical personnel - Health and hygiene
K1 Personal de salud - Enfermedades
K1 SARS-CoV-2
K1 COVID-19 (Disease) - Treatment
K1 COVID-19 vaccines
K1 Inmunology
K1 Vaccines
K1 Humoral response
K1 Adverse effects
K1 Medicamentos - Efectos adversos
K1 Virology
K1 Clinical medicine - Case studies
K1 32 Ciencias Médicas
K1 2412 Inmunología
K1 2412.10 Vacunas
K1 2420 Virología
AB The literature suggests that real-world data on the effectiveness and safety of the BNT162b2 vaccine depend on the characteristics of the vaccinated volunteers. The purpose of this study was to evaluate antibody responses and kinetics, established association with sociodemographic and clinical characteristics, and adverse reactions after complete vaccination with the BNT162b2 vaccine. A single-center prospective case series study was conducted with 112 eligible volunteers who were institutionalized elderly and health care workers with had a negative anti-SARS-CoV-2 IgG test prior to receiving the first dose of vaccine. At least one serological antibody test after each dose of vaccine was performed. Volunteers with a positive SARS-CoV-2 PCR test before vaccination were excluded. A chemiluminescent immunoassay anti-S1 antibody assay performed a serological evaluation. Both vaccine doses elicited positive IgG antibodies 3799.0 ± 2503.0 AU/mL and 8212.0 ± 4731.0 AU/mL after 20 days of the first and second doses of BNT162b2, respectively. Comirnaty® vaccine induced an immune response with antibody production against SARS-CoV-2 in 100% of participants, regardless of age (Spearman rho = −0.10, p-value = 0.312), body mass index (Spearman rho = 0.05, p-value = 0.640), blood group first dose (p-value for Kruskal–Wallis test = 0.093) and second dose (p-value for Kruskal–Wallis test = 0. 268), number of drugs (Spearman rho = −0.07, p-value = 0.490), and number of chronic diseases first dose (p-value for Kruskal–Wallis test = 0.632) and second dose (p-value for Kruskal–Wallis test = 0.510). IgG antibodies to SARS-CoV-2 were intensely elevated after the second administration of the BNT162b2 vaccine. The higher the titer of anti-peptide IgG antibodies generated after the first dose of vaccine, the higher the titer generated by the second dose of vaccine (Spearman rho = 0.86, p-value < 0.001) and the total antibody titer (Spearman rho = 0.93, p-value < 0.001). Furthermore, no serious adverse effects were reported among participants, although mild to moderate adverse effects (local or systemic) were reported after both doses of the BNT162b2 vaccine, being more frequent after the first dose of the vaccine. No participants showed a positive PCR. The BNT162b2 vaccine induces a robust and rapid antibody response regardless of participant characteristics. The second dose might be especially important because of the increased immunogenicity it produces and the possible temporal distancing of the interval between doses. In general, the vaccines were well tolerated.
PB MDPI
SN 2076-393X
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/61941
UL https://uvadoc.uva.es/handle/10324/61941
LA eng
NO Vaccines, 2022, Vol. 10, Nº. 8, 1170
NO Producción Científica
DS UVaDOC
RD 27-dic-2024